Abstract
Triple-negative breast cancer (TNBC) is one of the most fatal and aggressive type of cancer in younger population. TNBC is poorly diagnosed, detected only at later stages with low survival rate and high chemoresistance. The expression of the cancer stem cell (CSC) markers has critical role in chemoresistance and recurrence. In this review, focus is on potential CSC targets and treatment strategies for TNBC. Inhibition of proliferative genes involved in TNBC can reduce its spread and tumor invasiveness. Also, inhibiting proteins that are involved in signaling pathways that help in the expression of CSC markers can improve chemosensitivity. Thus, combining inhibition of critical genes and proteins can be a potential therapy strategy. Therefore, functioning of γ-secretase inhibitors (GSI-IX, Presenilin1/2, Pen-2, Nicastrin, APH-1), BEZ235, GANT61 inhibitor, NVP-LDE225, GSK3β inhibitor, AMPK activator (Aza- podophyllotoxin, demethoxycurcumin, N, N-diarylurea FND-4b) and MYC inhibitors (Triptolide, Quinoxalines) in TNBC are reviewed extensively.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
